The results showed that MSCs can be genetically engineered to express cytokines and augment the immune response via enhancing CD4+ and CD8+ T-cell infiltration and then stimulating subsequent cascade immune networks; these modified MSCs can be exploited to a therapeutic advantage against gliomas. This evidence concerns the gene CD8A and central nervous system cancer.